Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...

Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow ...

After some initial slick spots early this morning, today looks very nice for the busy travel day. A messy storm moves through Thanksgiving Day though. It could feature light snow and mix to start ...

Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...

A lengthy process with too many requirements was the main reason given (72%) for a below average experience applying through an employer website Almost two-thirds (63%) of applicants have been ...